Advertisement

Pharmaka zur Behandlung von Funktionsstörungen des endokrinen Systems

  • E. Oberdisse
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Der wichtigste Weg für die Zell-zu-Zell-Kommunikation des Organismus verläuft über die Synthese von chemischen Botenstoffen, die in bestimmten Zellen synthetisiert und sezerniert werden und ihre Botschaft dann an andere Zellen weitergeben. Dies ist der Weg, über den die klassischen Hormone, Gewebshormone, Wachstumsfaktoren und Neurotransmitter wirken.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agarwal MK (1994) Perspectives in receptor-mediated mineralocorticoid hormone action. Pharmacol Rev 46:67–87PubMedGoogle Scholar
  2. Baird DT, Glasier AF (1993) Hormonal contraception. N Engl J Med 328:1543–1549PubMedCrossRefGoogle Scholar
  3. Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14:436–441PubMedCrossRefGoogle Scholar
  4. Barrett-Connor E (1992) Risks and benefits of replacement estrogen. Annu Rev Med 43:239–251PubMedCrossRefGoogle Scholar
  5. Beato M (1989) Gene regulation by steroid hormones. Cell 56:335–344PubMedCrossRefGoogle Scholar
  6. Belchetz PE (1994) Hormonal treatment of postmenopausal women. N Engl J Med 330:1062–1071PubMedCrossRefGoogle Scholar
  7. Bell GI, Reisine T (1993) Molecular biology of somatostatin receptors. Trends Neurosci 16:34–38PubMedCrossRefGoogle Scholar
  8. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293–297PubMedCrossRefGoogle Scholar
  9. Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1–80PubMedGoogle Scholar
  10. Blundell J (1991) Pharmacological approaches to appetite suppression. Trends Pharmacol Sci 12:147–157PubMedCrossRefGoogle Scholar
  11. Boess FG, Martin IL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33:275–317PubMedCrossRefGoogle Scholar
  12. Brent GA (1994) The molecular basis of thyroid hormone action. N Engl J Med 331:847–853PubMedCrossRefGoogle Scholar
  13. Brogden RN, Goa KL, Faulds D (1993) Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45:348–409CrossRefGoogle Scholar
  14. Conn PM, Crowley WF (1991) Gonadotropin-releasing hormone and its analogs. Annu Rev Med 45:391–405CrossRefGoogle Scholar
  15. Cooper DS (1984) Antithyroid drugs. N Engl J Med 311:1353–1362PubMedCrossRefGoogle Scholar
  16. Davidson FF, Dennis EA (1989) Biological relevance of lipo-cortins and related proteins as inhibitors of phospholipase A2. Biochem Pharmacol 38:3645–3651PubMedCrossRefGoogle Scholar
  17. Dewaal RMW (1994) The anti-inflammatory activity of glucocorticoids. Mol Biol Reports 19:81–88CrossRefGoogle Scholar
  18. Dray A, Perkins M (1993) Bradykinin and inflammatory pain. Trends Neurosci 16:99–104PubMedCrossRefGoogle Scholar
  19. Drife JO, Baird DT (eds) (1993) Contraception. Br Med Bull Vol 49/1, Churchill Livingstone, EdingburghGoogle Scholar
  20. Evans RM (1988) The steroid and thyroid hormone super-family. Science 240:889–895PubMedCrossRefGoogle Scholar
  21. Farmer SG, Burch RM (1992) Biochemical and molecular pharmacology of kinin receptors. Annu Rev Pharmacol Toxicol 32:511–536PubMedCrossRefGoogle Scholar
  22. Flower RJ, Rothwell NJ (1994) Lipocortin-1: Cellular mechanisms and clinical relevance. Trends Pharmacol Sci 15:71–76PubMedCrossRefGoogle Scholar
  23. Franklyn JA (1994) The management of hyperthyroidism. N Engl J Med 330:1731–1738PubMedCrossRefGoogle Scholar
  24. Frey BM, Frey FJ (1990) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19:126–146PubMedCrossRefGoogle Scholar
  25. Funder JW (1993) Aldosterone action. Annu Rev Physiol 55:115–130PubMedCrossRefGoogle Scholar
  26. Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocor-ticoid action: Target tissue specificity is enzyme, not receptor-mediated. Science 242:583–585PubMedCrossRefGoogle Scholar
  27. Griffin JE, Ojeda SR (eds) (1992) Textbook of endocrine physiology, 2nd edn. Oxford University Press, New York OxfordGoogle Scholar
  28. Helfer EL, Rose LI (1989) Corticosteroids and adrenal suppression: Characterising and avoiding the problem. Drugs 38:838–845PubMedCrossRefGoogle Scholar
  29. Hesch RD (Hrsg) (1989) Endokrinologie Teil A: Grundlagen. In: Gerok W, Hartmann F, Schuster H-P (Hrsg) Innere Medizin der Gegenwart, Bd 4. Urban & Schwarzenberg, München Wien BaltimoreGoogle Scholar
  30. Hesch RD (Hrsg) (1989) Endokrinologie Teil B: Krankheitsbilder. In: Gerok W, Hartmann F, Schuster H-P (Hrsg) Innere Medizin der Gegenwart. Bd 5. Urban & Schwarzenberg, München Wien BaltimoreGoogle Scholar
  31. Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233–236PubMedCrossRefGoogle Scholar
  32. Kaunitz AM, Rosenfield A (1993) Injectable contraception with depot medroxyprogesterone acetat: Current status. Drugs 45:857–865PubMedCrossRefGoogle Scholar
  33. Khaw KT (ed) (1992) Hormone replacement therapy. Br Med Bull Vol 48/2, Churchill divingstone, EdinburghGoogle Scholar
  34. Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 323:645–655PubMedCrossRefGoogle Scholar
  35. Liscovitch M, Cantley LC (1994) Lipid second messengers. Cell 77:329–334PubMedCrossRefGoogle Scholar
  36. Lucas PC, Granner DK (1992) Hormone response domains in gene transcription. Annu Rev Biochem 61:1131–1173PubMedCrossRefGoogle Scholar
  37. Lukas SE (1993) Current perspectives on anabolic-androgenic steroid abuse. Trends Pharmacol Sci 14:61–68PubMedCrossRefGoogle Scholar
  38. Markham A, Sorkin EM (1993) Ondansetron: An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931–952PubMedCrossRefGoogle Scholar
  39. Martin GR, Humphrey PPA (1994) Receptors for 5-hydroxy-tryptamine: Current perspectives on classification and nomenclature. Neuropharmacology 33:261–273PubMedCrossRefGoogle Scholar
  40. McEwen BS (1991) Non-genomic and genomic effects of steroids on neuronal activity. Trends Pharmacol Sci 12:141–147PubMedCrossRefGoogle Scholar
  41. Meyers FH, Jawetz E, Goldfien A (1975): Lehrbuch der Pharmakologie. Springer, Berlin, Heidelberg, New YorkCrossRefGoogle Scholar
  42. Miller WL (1988) Molecular biology of steroid hormone synthesis. Endocrinol Rev 9:295–318CrossRefGoogle Scholar
  43. Moskowitz MA, Cutrer FM (1993) Sumatriptan: A receptor-targeted treatment for migraine. Annu Rev Med 44:145–154PubMedCrossRefGoogle Scholar
  44. Muller M, Renkawitz R (1991) The glucocorticoid receptor. Biochim Biophys Acta 1088:171–182PubMedGoogle Scholar
  45. Musser JH, Kreft AF (1992) 5-Lipoxygenase: Properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. J Med Chem 35:2501–2524PubMedCrossRefGoogle Scholar
  46. Neely EK, Rosenfeld RG (1994) Use and abuse of human growth hormone. Annu Rev Med 45:407–420PubMedCrossRefGoogle Scholar
  47. Petersen OH, Petersen CCH, Kasai H (1994) Calcium and hormone action. Annu Rev Physiol 56:297–319PubMedCrossRefGoogle Scholar
  48. Plosker GL, McTavish D (1994) Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 47:622–651PubMedCrossRefGoogle Scholar
  49. Power RF, Conneely OM, O’Malley BW (1992) New insights into activation of the steroid hormone receptor super-family. Trends Pharmacol Sci 13:318–323PubMedCrossRefGoogle Scholar
  50. Raiteri M (1994) Functional studies of neurotransmitter receptors in human brain. Life Sci 54:1635–1647PubMedCrossRefGoogle Scholar
  51. Raynal P, Pollard HB (1994) Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1197:63–93PubMedGoogle Scholar
  52. Reinwein D, Röher H-D, Emrich D (1993) Therapie der Hyperthyreose: Aktueller Stand. Dtsch Med Wochenschr 118:1036–1043PubMedCrossRefGoogle Scholar
  53. Reznek RH, Armstrong P (1994) The adrenal gland. Clin Endocrinol 40:561–576CrossRefGoogle Scholar
  54. Schneider WE (1978): Ovar. In: Labhardt A: Klinik der inneren Sekretion. Springer, Berlin, Heidelberg, New York. 523–686Google Scholar
  55. Shimizu T, Honda Z, Nakamura M, Bito H, Izumi T (1992) Platelet-activating factor receptor and signal transduction. Biochem Pharmacol 44:1001–1008PubMedCrossRefGoogle Scholar
  56. Shimizu T, Wolfe LS (1990) Arachidonic acid cascade and signal transduction. J Neurochem 55:1–15PubMedCrossRefGoogle Scholar
  57. Simons FER, Simons KJ (1994) The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 330:1663–1670PubMedCrossRefGoogle Scholar
  58. Smith WL (1989) The eicosanoids and their biochemical mechanisms of action. Biochem J 259:315–324PubMedGoogle Scholar
  59. Snyder DW, Fleish JH (1989) Leukotriene receptor antagonists as potential therapeutic agents. Annu Rev Pharmacol Toxicol 29:123–143PubMedCrossRefGoogle Scholar
  60. Spitz IM, Bardin CW (1993) Mifepristone (RU 486) — a modulator of progestin and glucocorticoid action. N Engl J Med 329:404–412PubMedCrossRefGoogle Scholar
  61. Strauss RH, Yesalis CE (1991) Anabolic steroids in the athlete. Annu Rev Med 42:449–457PubMedCrossRefGoogle Scholar
  62. Strobl JS, Thomas MJ (1994) Human growth hormone. Pharmacol Rev 46:1–34PubMedGoogle Scholar
  63. Tata JR (1967): Ribosomes and thyroid hormones. In: Karlson P (Hrsg.): Wirkungsmechanismen der Hormone. Spinger, Berlin, Heidelberg, New York, 87–103Google Scholar
  64. Toft AD (1994) Thyroxine therapy. N Engl J Med 331:174–180PubMedCrossRefGoogle Scholar
  65. Ur E, Grossman A (1992) Corticotropin-releasing hormone in health and disease: An update. Acta Endocrinol 127:193–199PubMedGoogle Scholar
  66. Vance ML (1994) Hypopituitarism. N Engl J Med 330: 1651–1662PubMedCrossRefGoogle Scholar
  67. Wehling M, Christ M, Gerzer R (1993) Aldosterone-specific membrane receptors and related rapid, non-genomic effects. Trends Pharmacol Sci 14:1–4PubMedCrossRefGoogle Scholar
  68. Weiss RE, Refetoff S (1992) Thyroid hormone resistance. Annu Rev Med 43:363–375PubMedCrossRefGoogle Scholar
  69. White PC (1994) Disorders of aldosterone biosysthesis and action. N Engl J Med 331:250–258PubMedCrossRefGoogle Scholar
  70. Wilckens T (1995) Glucocorticoids and immune function: physiological relevance and the pathogenic potential of hormonal dysfunction. Trends Pharmacol Sci 16:193–197PubMedCrossRefGoogle Scholar
  71. Woodruff TK, Mather JP (1995) Inhibin, activin and the female reproductive axis. Annu Rev Physiol 57:219–244PubMedCrossRefGoogle Scholar
  72. Yen PM, Chin WW (1994) New advances in understanding the molecular mechanisms of thyroid hormone action. Trends Endocrinol Metabol 5:65–72CrossRefGoogle Scholar
  73. Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401–458PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Oberdisse

There are no affiliations available

Personalised recommendations